Study on the evaluation of the safety and efficacy of Sofosbuvir in participants with mild coronavirus in outpatients (COVID-19)

Phase 3

Completed

• Conditions: COVID-19.; COVID-19; U07.1

• Registration Number: IRCT20201127049505N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 360

Inclusion Criteria

Outpatients presented with positive PCR and mild clinical signs
without pulmonary involvement on CT scan
As defined by patient with sore throat
dry cough
loss of sense of smell and taste
nausea and vomiting
O2 Sat = 95
T <38
RR <24
stable pulse and blood pressure
body aches

Exclusion Criteria

y>18
Organ transplant
Severe skin history including TEN or Steven JohnsonAllergy to the studied drug
The patient has previously been treated with this drug for other reasons
Hepatitis C
Not able to take pills
Lack of awareness
Be treated with anticonvulsant drugs
Have fever and respiratory symptoms from 2 weeks ago
Be treated with immunosuppressive drugs
Be pregnant or breastfeeding
1 month ago received antiviral drugs for Covid-19
ESRD
Advance CKD
Advance liver disease
Pulmonary Advance Disease
Cardiac Advance Disease
Advance Disease Hematology
Solid tumor
Cancer of neurological diseases such as CVA
your situationG6PD deficient
Be pregnant or breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Shortness of breath. Timepoint: day 14 or sooner at the discretion of the physician. Method of measurement: Clinical evaluation.